Left Atrial Appendage Closure Is Safe with the New Devices

Left atrial appendage closure (LAAC) in non-valvular atrial fibrillation with high risk of bleeding has shown promising results with first generation devices (with the Watchman) in the different studies.

El cierre de orejuela es seguro con los nuevos dispositivos

At present, we have a more modern device, the Watchman FLX, but we do not have much information about it. 

To gather more data, researchers looked at 200 consecutive patients from the FLX‐IEST Registry (Watchman FLX data from two high‐volume Sicilian centers) receiving LAAC with Watchman FLX.

Mean age was 77, 67% were men, 57% had kidney function deterioration, 41% were diabetic, 55% had coronary artery disease, 18% were in functional class III, 55% had cardiac failure, 47% ejection fraction, 29% stroke or transient ischemic attack, 56% prior bleeding. 

CHA2DS2‐VASc score was 5 and HAS‐BLED score was 4.

LAAC indications were symptomatic hemorrhage, need for triple antithrombotic therapy, gastrointestinal bleeding, and oral anticoagulation intolerance. 

93% was guided by transesophageal eco-Doppler, 48% was done under general anesthesia, 45% under conscious sedation and 7% under local anesthesia. 

Read also: Ticagrelor Monotherapy: Valid after 12 Months?

Procedural success was 99.5%. >5 mm leak was seen in one patient only and <5 mm in two patients, and there was no embolization. Major bleeding rate was 1%; there was one death related to major bleeding. 

At discharge, 85% received dual antiplatelet therapy (DAPT).

At 272±173 day follow up, there was 4.1% major bleeding, 0.6% fatal bleeding and 2.3% non-device-related stroke. 

Conclusion

This study showed a higher procedural success rate with Watchman-FLX in a high-risk population. According to author experience, the main advantage included easy implantation and repositioning, absence of embolization, good left atrial appendage sealing and low complications rate at follow up. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Real‐world experience with the new Watchman FLX device: Data from two high‐volume Sicilian centers. The FLX‐iEST registry.

Reference: Giampiero Vizzari, et al. Catheter Cardiovasc Interv. 2022;100:154–160.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...